Influenza Clinical Trial
Official title:
A Phase I Double-Blind, Placebo-Controlled, Dose-Escalating Study to Evaluate the Safety and Tolerability of Topical Nasal Poly-ICLC
This study will examine the safety of an experimental medication called Poly-ICLC, developed
for preventing or reducing the severity of infections from influenza and other viruses
acquired through the nose, mouth and lungs. The study is divided into two parts, in which
Poly-ICLC is tested at different dose levels.
Healthy people between 18 and 70 years of age who have no chronic medical problems may be
eligible for this study. Participants undergo the following procedures:
Part I
- Up to 7 days before Poly-ICLC administration: Medical history, physical examination and
blood tests.
- Day 1: Nasal wash and Poly-ICLC administration. A small amount of salt water is placed
into the front of the nose and then suctioned out. Poly-ICLC is then squirted into each
nostril, one after the other, at a dose of 0.25, 0.5 or 1 mg. A small number of subjects
are given a placebo (a solution with no active ingredient.) Subjects are observed in the
clinic for 30 minutes after treatment.
- Day 2: Subjects receive a second nasal wash and repeat blood tests. They keep a diary
card for 1 week, recording any drug side effects.
- Day 5: Subjects have repeat blood tests and a review of their diary card. The keep a
diary card for another 3 weeks.
- Day 12: Subjects are contacted by phone to review their diary card.
- Day 28: Subjects are contacted by phone to review their diary card.
Part II
- Up to 7 days before Poly-ICLC administration: Medical history, physical examination and
blood tests.
- Day 1: Nasal wash and Poly-ICLC administration. Same as above for Part I participants.
- Day 3: Subjects receive a second dose of medication and are observed again for 30
minutes.
- Day 4: Subjects receive a second nasal wash and repeat blood tests. They keep a diary
card for 1 week, recording any drug side effects.
- Day 7: Subjects have repeat blood tests and a review of their diary card. The keep a
diary card for another 3 weeks.
- Day 14: Subjects are contacted by phone to review their diary card.
- Day 28: Subjects are contacted by phone to review their diary card.
Polyinosinic-Polycytidylic acid stabilized with polylysine and carboxymethylcellulose
(Poly-ICLC), a stabilized double stranded RNA (dsRNA) therapeutic viral mimic activating
innate and adaptive immunity, has been in extensive preclinical and investigational clinical
therapeutic use as an intramuscular and intravenous compound, most recently in oncology
applications. Only recently have the mechanisms of action been more fully elucidated,
including induction of interferons, cytokines, and chemokines. Recognizing this, the
infectious disease applications have been pursued in in vitro and animal models. Intranasal
Poly-ICLC provides protection against mortality in animal models for multiple highly
pathogenic viruses including influenza, severe acute respiratory distress syndrome (SARS),
smallpox and Ebola. As its effects are not dependant on knowing the causative virus, an
effective compound that could be protective against several unknown respiratory viruses has
significant clinical appeal. While there is clinical safety data for intramuscular (IM)
Poly-ICLC, no clinical studies of nasal application of Poly-ICLC have been done.
This study is a phase I safety and pharmacokinetic trial of nasally applied Poly-ICLC. Human
volunteers will be administered increasing doses of nasal Poly-ICLC, with serial evaluation
of safety, tolerability, as well as exploratory markers of immune activation.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05523089 -
The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults
|
Phase 2 | |
| Completed |
NCT05009251 -
Using Explainable AI Risk Predictions to Nudge Influenza Vaccine Uptake
|
N/A | |
| Completed |
NCT03282240 -
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
|
Phase 3 | |
| Completed |
NCT00971425 -
Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1)
|
Phase 3 | |
| Completed |
NCT00968539 -
Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults
|
Phase 3 | |
| Completed |
NCT00968526 -
Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults
|
Phase 3 | |
| Completed |
NCT05525494 -
Patient Portal Flu Vaccine Reminders (5)
|
N/A | |
| Completed |
NCT04074928 -
Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects
|
Phase 3 | |
| Completed |
NCT04695717 -
This Study Was Conducted to Evaluate the Safety and Immunogenicity of IVACFLU-S Produced in Children From 6 Months to Under 18 Years Old and the Elderly Over 60 Years Old in Vietnam
|
Phase 3 | |
| Completed |
NCT05012163 -
Lottery Incentive Nudges to Increase Influenza Vaccinations
|
N/A | |
| Completed |
NCT03888989 -
Response to Influenza Vaccine During Pregnancy
|
Phase 1 | |
| Completed |
NCT04109222 -
Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively
|
Phase 4 | |
| Completed |
NCT02587221 -
Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age
|
Phase 3 | |
| Completed |
NCT03453801 -
The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection
|
Phase 1 | |
| Completed |
NCT01440387 -
A Study of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older
|
Phase 3 | |
| Terminated |
NCT01195779 -
Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children
|
Phase 2 | |
| Completed |
NCT03321968 -
Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults
|
Phase 3 | |
| Completed |
NCT00972517 -
Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children
|
Phase 3 | |
| Completed |
NCT04570904 -
Broadening Our Understanding of Early Versus Late Influenza Vaccine Effectiveness
|
||
| Recruiting |
NCT03331991 -
Prevention of Influenza and Other Wintertime Respiratory Viruses Among Healthcare Professionals in Israel
|
N/A |